1. Home
  2. FLYW vs IOVA Comparison

FLYW vs IOVA Comparison

Compare FLYW & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flywire Corporation Voting

FLYW

Flywire Corporation Voting

HOLD

Current Price

$13.64

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.49

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLYW
IOVA
Founded
2009
2007
Country
United States
United States
Employees
1400
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
FLYW
IOVA
Price
$13.64
$3.49
Analyst Decision
Buy
Buy
Analyst Count
14
10
Target Price
$16.21
$9.00
AVG Volume (30 Days)
1.5M
14.2M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
450.00
14.84
EPS
0.11
N/A
Revenue
$623,025,000.00
N/A
Revenue This Year
$19.68
$47.74
Revenue Next Year
$15.25
$40.31
P/E Ratio
$123.05
N/A
Revenue Growth
26.59
N/A
52 Week Low
$9.05
$1.64
52 Week High
$15.25
$5.63

Technical Indicators

Market Signals
Indicator
FLYW
IOVA
Relative Strength Index (RSI) 62.43 45.56
Support Level $13.30 $2.05
Resistance Level $14.04 $4.33
Average True Range (ATR) 0.52 0.29
MACD 0.14 -0.02
Stochastic Oscillator 83.57 21.23

Price Performance

Historical Comparison
FLYW
IOVA

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: